文献速递中医内科针灸推拿中医康复

针刺时间参数与稳定期COPD疗效的剂量-效应系统评价与Meta分析

Exploration of quantitative-effectiveness association between acupuncture temporal parameters and stable chronic obstructive pulmonary disease: A systematic review and dose-response meta-analysis of randomized controlled trials.
PubMed 文献 · Complement Ther Med · 2024-05-10

该系统评价与剂量-效应Meta分析纳入17项RCT共1165例稳定期COPD患者,评估针刺次数、频率和疗程与FEV1%、6MWD等指标的关联。结果显示针刺可显著改善FEV1%、6MWD、SGRQ和CAT,且时间参数与疗效存在剂量-效应关系,12次针刺后可达到最小临床重要差异。

要点

  • 针刺可改善稳定期COPD患者FEV1%、6MWD、SGRQ和CAT。
  • 针刺次数、频率和疗程与FEV1%和6MWD改善呈剂量-效应关系。
  • 12次针刺后FEV1%和6MWD改善可达最小临床重要差异。

核心结论

  • 针刺可有效改善稳定期COPD患者的FEV1%、6MWD、SGRQ和CAT。
  • 针刺次数、频率和疗程与FEV1%和6MWD改善存在剂量-效应关系。
  • 12次针刺后可达最小临床重要差异。

研究设计与样本

  • 系统评价与剂量-效应Meta分析,检索8个数据库至2023年6月。
  • 最终纳入17项RCT,共1165例参与者。
  • 采用Cochrane偏倚风险工具和STRICTA标准独立评估。
  • 使用稳健误差元回归建模剂量-效应关系,R 4.3.1和Stata 15.0进行Meta分析。
  • 方案注册于PROSPERO,注册号CRD42023401406。

主要发现

  • 针刺组FEV1%较对照组提高MD=3.50(95%CI:2.05-4.95)。
  • 针刺组6MWD较对照组提高MD=47.39 m(95%CI:29.29-65.50)。
  • 针刺组SGRQ降低MD=-8.25(95%CI:-11.38至-5.12),CAT降低MD=-2.91(95%CI:-3.99至-1.83)。
  • 针刺次数和疗程与FEV1%、6MWD呈「Λ」曲线关系,频率与FEV1%、6MWD呈对数增长关系。
  • 12次针刺后FEV1%提高7.06%(95%CI:4.56-9.55),6MWD提高36.28 m(95%CI:20.37-52.20)。

关键数值与推荐

  • FEV1%改善峰值出现在18次针刺(MD=7.89,95%CI:5.33-10.45),6MWD改善峰值出现在45次针刺(MD=125.43,95%CI:72.80-178.07)。
  • 每周针刺使FEV1%提高4.14%(95%CI:2.55-5.72),6MWD提高42.49 m(95%CI:17.16-67.81)。
  • FEV1%最大效应对应每周3次(MD=6.00,95%CI:5.34-6.66),6MWD最大效应对应每日1次(MD=112.41,95%CI:77.27-147.56)。
  • 疗程28天时FEV1%提高4.74%(95%CI:3.73-5.75),6MWD提高47.34 m(95%CI:22.01-72.67)。
  • 疗程60天时FEV1%和6MWD改善达最高,分别为8.76%(95%CI:7.05-10.47)和88.06 m(95%CI:45.96-130.16)。

临床怎么用

  • 稳定期COPD患者可考虑针刺治疗以改善FEV1%、6MWD、SGRQ和CAT。
  • 12次针刺可作为达到最小临床重要差异的参考次数。
  • 中等频率(每周2-3次)持续60天可能使FEV1%改善最大,较高频率(每周5-7次)持续2个月可能使6MWD改善最大。
  • 不同指标的最佳针刺频率可能不同,需个体化选择。

局限性

  • 研究间存在显著异质性,但敏感性分析显示稳健性良好。
  • 需多中心、大规模随机对照试验确认结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Chronic Obstructive Pulmonary Disease (COPD) is a globally common chronic respiratory disease with a high morbidity and mortality rate. Acupuncture has been proven effective for COPD. A dose-response meta-analysis was conducted to assess the correlation between the acupuncture temporal parameters(session, frequency, and duration) and its effectiveness in patients with stable COPD. METHODS: Acupuncture randomized controlled trials on COPD were searched in eight databases from their inception to June 2023. The "doses" were defined as the acupuncture session, frequency, and duration. The outcomes mainly included Forced Expiratory Volume in one-second rate (FEV1%) and Six-minute Walking Distance (6MWD). The assessment of bias risk and literature quality were conducted independently using the Cochrane risk of bias tool and the Standards for reporting interventions in clinical trials of acupuncture. The dose-response relationship was modeled using robust error element regression, and meta-analysis was operated by R 4.3.1 and Stata 15.0. The protocol was registered in PROSPERO with the registration number CRD42023401406. RESULT: Out of 1669 records, 17 RCTs with 1165 participants were finally included in the meta-analysis. There was notable heterogeneity among the studies, but sensitivity analysis demonstrated good robustness. The findings revealed a significant improvement in the following outcomes for stable COPD patients in the acupuncture group: FEV1% (MD=3.50, 95%CI: 2.05-4.95), 6MWD (MD=47.39, 95%CI: 29.29-65.50), St. George's respiratory questionnaire (SGRQ; MD=-8.25, 95%CI: -11.38 to -5.12); COPD assessment test (CAT; MD=-2.91, 95%CI: -3.99 to -1.83). The relationship between the acupuncture session, duration, and FEV1%, 6MWD followed a "Λ" curve pattern, while the relationship between acupuncture frequency and FEV1%, 6MWD exhibited logarithmic growth. Firstly, After 12 acupuncture sessions, FEV1% and 6MWD increased by 7.06% (95%CI: 4.56-9.55) and 36.28 m (95%CI: 20.37-52.20), respectively. The peak improvement in FEV1% and 6MWD was observed after 18 acupuncture sessions (MD=7.89, 95% CI: 5.33-10.45) and 45 sessions (MD=125.43, 95% CI: 72.80-178.07) each. Additionally, weekly acupuncture resulted in a 4.14% improvement in FEV1% (95% CI: 2.55-5.72) and a 42.49 m increase in 6MWD (95%CI: 17.16-67.81). Notably, the maximum effects on FEV1% and 6MWD improvement were achieved with different acupuncture frequencies, specifically three times a week (MD=6.00, 95% CI: 5.34-6.66) and once a day(MD=112.41, 95% CI: 77.27-147.56), respectively. Furthermore, after a 28-day duration of acupuncture treatment, FEV1% increased by 4.74% (95% CI: 3.73-5.75) and 6MWD increased by 47.34 m (95%CI: 22.01-72.67). During 60 days of acupuncture treatment, the FEV1% and 6MWD improvement reached their highest levels at 8.76% (95% CI: 7.05-10.47) and 88.06 m (95% CI: 45.96-130.16), respectively. CONCLUSION: Acupuncture was effective in improving FEV1%, 6MWD, SGRQ, and CAT in patients with stable COPD. There was a dose-response relationship between the time parameters of acupuncture (session, frequency, and duration) and the efficacy of COPD treatment (FEV1% and 6MWD). The minimal clinically important difference could be achieved after 12 acupuncture sessions. Acupuncture with a medium-frequency (2-3 times per week) over 60 days may result in the greatest improvement in FEV1%, while higher-frequency acupuncture (5-7 times per week) for 2 months may lead to the maximum improvements in 6MWD. It indicated that the optimal acupuncture duration for different indicators remains consistent, while the optimal frequencies may differ. To confirm these results, it is necessary to conduct multicenter, large-scale randomized controlled trials. ETHICS AND DISSEMINATION: Ethical approval is not required for literature-based studies. The results will be published in peer-reviewed journals or conferences.

来源:Complement Ther Med,查看原文。版权归原作者所有。

引用

  1. Luo Q, Sun M, Xu G, et al. Exploration of quantitative-effectiveness association between acupuncture temporal parameters and stable chronic obstructive pulmonary disease: A systematic review and dose-response meta-analysis of randomized controlled trials. Complement Ther Med. 2024. PMID: 38734186. doi:10.1016/j.ctim.2024.103048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。